Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy.
Cheson
B D
BD
Clinical Investigations Branch, National Cancer Institute, Bethesda, MD 20892-7436, USA.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D005544:Forecasting; D006133:Growth Substances / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000494:pharmacology / Q000627:therapeutic use; D000077150:Oxaliplatin
D020533:Angiogenesis Inhibitors; D006133:Growth Substances; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin